NASDAQ:ADPT Adaptive Biotechnologies (ADPT) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free ADPT Stock Alerts $2.58 +0.07 (+2.79%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$2.45▼$2.7350-Day Range$2.34▼$4.2752-Week Range$2.28▼$9.08Volume1.52 million shsAverage Volume1.62 million shsMarket Capitalization$374.33 millionP/E RatioN/ADividend YieldN/APrice Target$6.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Adaptive Biotechnologies alerts: Email Address Adaptive Biotechnologies MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside163.6% Upside$6.80 Price TargetShort InterestBearish6.57% of Float Sold ShortDividend StrengthN/ASustainability-0.79Upright™ Environmental ScoreNews Sentiment0.14Based on 2 Articles This WeekInsider TradingSelling Shares$428,090 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.31) to ($1.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.73 out of 5 starsMedical Sector221st out of 909 stocksBiological Products, Except Diagnostic Industry27th out of 155 stocks 3.3 Analyst's Opinion Consensus RatingAdaptive Biotechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAdaptive Biotechnologies has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.57% of the float of Adaptive Biotechnologies has been sold short.Short Interest Ratio / Days to CoverAdaptive Biotechnologies has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Adaptive Biotechnologies has recently increased by 7.57%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAdaptive Biotechnologies does not currently pay a dividend.Dividend GrowthAdaptive Biotechnologies does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAdaptive Biotechnologies has received a 61.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Basic medical research services", "Scientific databases", and "Medical laboratory automation systems" products. See details.Environmental SustainabilityThe Environmental Impact score for Adaptive Biotechnologies is -0.79. Previous Next 2.3 News and Social Media Coverage News SentimentAdaptive Biotechnologies has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Adaptive Biotechnologies this week, compared to 3 articles on an average week.Search Interest14 people have searched for ADPT on MarketBeat in the last 30 days. This is an increase of 180% compared to the previous 30 days.MarketBeat Follows18 people have added Adaptive Biotechnologies to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adaptive Biotechnologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $428,090.00 in company stock.Percentage Held by InsidersOnly 5.20% of the stock of Adaptive Biotechnologies is held by insiders.Percentage Held by Institutions99.17% of the stock of Adaptive Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Adaptive Biotechnologies are expected to grow in the coming year, from ($1.31) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adaptive Biotechnologies is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adaptive Biotechnologies is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdaptive Biotechnologies has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About Adaptive Biotechnologies Stock (NASDAQ:ADPT)Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.Read More ADPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADPT Stock News HeadlinesApril 17, 2024 | globenewswire.comAdaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024April 17, 2024 | americanbankingnews.comShort Interest in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Increases By 7.6%April 24, 2024 | Whats On Finance (Ad)Putin and other countries have a planDid you catch that bombshell Tucker Carlson interview with Vladimir Putin? It’s not about if you like Tucker or think Putin is the devil or whatever. It's all about the fact that the US dollar might be taking a back seat... and soon. April 16, 2024 | bizjournals.comAdaptive Biotechnologies names new CFO, restructures business linesApril 13, 2024 | msn.comAdaptive Foundation offers free fitness classes for veterans, first responders in TylerApril 9, 2024 | msn.comThe Center for Adaptive Riding hosts open house for new locationApril 4, 2024 | uk.investing.comAdaptive Biotechnologies CFO resigns, successor namedApril 2, 2024 | marketwatch.comAdaptive Biotechnologies to Restructure Businesses After ReviewApril 24, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 2, 2024 | globenewswire.comAdaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 RevenueApril 1, 2024 | msn.comCenter for Adaptive Riding hosts open house at new facilityMarch 30, 2024 | msn.comLocal family hosts ‘Adaptive Easter Egg Hunt’March 28, 2024 | finance.yahoo.comNetcracker Continues Its Support of the U.S. Paralympic Ski and Snowboard Team at Adaptive Spirit 2024March 27, 2024 | investorplace.comThe 7 Best Penny Stocks to Buy in Q2 2024March 27, 2024 | globenewswire.comAdaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024March 27, 2024 | finance.yahoo.comCanada Adaptive Clothing Market to Reach US$ 79.08 Million by 2031, Rising at a CAGR of 8.7% | Report by CoherentMIMarch 23, 2024 | msn.comAdaptive surfers dazzle at Byron Bay as they push for acceptance into ParalympicsMarch 19, 2024 | finance.yahoo.comTeam behind popular Falcon AI models unveils new startup with $20 million in funding aimed at helping companies tailor LLMs for businessMarch 16, 2024 | forbes.comXBox Adaptive Controller Review: A Necessary AccessoryMarch 12, 2024 | sports.yahoo.comAre algorithms going to revolutionize MTB suspension? RockShox releases new Flight Attendant with Adaptive Ride DynamicsMarch 12, 2024 | tmcnet.comAdaptive ML Raises $20M to Help Companies Build Unique GenAI ExperiencesMarch 10, 2024 | msn.comBoston-based film ‘American Fiction’ wins Oscar for Best Adaptive ScreenplayMarch 6, 2024 | msn.comAdaptive Adventures returns to MarquetteMarch 1, 2024 | msn.comSweet victory: Bakersfield ARC Ball Hogs win basketball tournament in Adaptive Sports LeagueFebruary 23, 2024 | msn.comAdaptive skiing helps people with disabilities ski and compete at SnowbowlFebruary 22, 2024 | globenewswire.comAdaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare ConferenceFebruary 22, 2024 | sports.yahoo.comUSGA announces cut, new exemption categories for 2024 U.S. Adaptive OpenSee More Headlines Receive ADPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptive Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today4/23/2024Next Earnings (Confirmed)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ADPT CUSIPN/A CIK1478320 Webwww.constructionpartners.net Phone(206) 659-0067Fax206-659-0667Employees709Year Founded2009Price Target and Rating Average Stock Price Target$6.80 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+164.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-225,250,000.00 Net Margins-132.29% Pretax Margin-132.32% Return on Equity-53.65% Return on Assets-27.24% Debt Debt-to-Equity RatioN/A Current Ratio4.66 Quick Ratio4.50 Sales & Book Value Annual Sales$170.28 million Price / Sales2.19 Cash FlowN/A Price / Cash FlowN/A Book Value$2.13 per share Price / Book1.21Miscellaneous Outstanding Shares145,090,000Free Float137,547,000Market Cap$372.88 million OptionableOptionable Beta1.25 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Chad M. Robins M.B.A. (Age 50)Co-Founder, CEO & Chairman Comp: $1.19MMs. Julie Rubinstein (Age 52)President & COO Comp: $760.46kDr. Harlan S. Robins Ph.D. (Age 51)Co-Founder & Chief Scientific Officer Comp: $759.61kMr. Tycho W. Peterson (Age 50)Chief Financial Officer Comp: $539.73kMr. Kyle Piskel (Age 40)VP & Principal Accounting Officer Comp: $375.9kDr. Sharon Benzeno Ph.D. (Age 50)Chief Commercial Officer of Immune Medicine Comp: $671.29kMr. Christopher Carlson Ph.D.FounderKarina CalzadillaVice President of Investor RelationsMs. Stacy L. Taylor (Age 64)Senior VP, General Counsel & Corporate Secretary Mr. Francis T. Lo (Age 43)Chief People Officer More ExecutivesKey CompetitorsiTeos TherapeuticsNASDAQ:ITOSLexeo TherapeuticsNASDAQ:LXEOOcugenNASDAQ:OCGNVoyager TherapeuticsNASDAQ:VYGRHumacyteNASDAQ:HUMAView All CompetitorsInsiders & InstitutionsSumitomo Mitsui Trust Holdings Inc.Sold 334,952 shares on 4/19/2024Ownership: 4.257%First Trust Direct Indexing L.P.Bought 14,544 shares on 4/19/2024Ownership: 0.010%Chad M RobinsSold 48,673 sharesTotal: $166,948.39 ($3.43/share)Tycho PetersonSold 15,456 sharesTotal: $53,168.64 ($3.44/share)Julie RubinsteinSold 39,070 sharesTotal: $135,572.90 ($3.47/share)View All Insider TransactionsView All Institutional Transactions ADPT Stock Analysis - Frequently Asked Questions Should I buy or sell Adaptive Biotechnologies stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adaptive Biotechnologies in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ADPT shares. View ADPT analyst ratings or view top-rated stocks. What is Adaptive Biotechnologies' stock price target for 2024? 6 brokers have issued 12 month price objectives for Adaptive Biotechnologies' shares. Their ADPT share price targets range from $5.00 to $10.00. On average, they expect the company's share price to reach $6.80 in the next year. This suggests a possible upside of 163.6% from the stock's current price. View analysts price targets for ADPT or view top-rated stocks among Wall Street analysts. How have ADPT shares performed in 2024? Adaptive Biotechnologies' stock was trading at $4.90 at the beginning of 2024. Since then, ADPT stock has decreased by 47.3% and is now trading at $2.58. View the best growth stocks for 2024 here. Are investors shorting Adaptive Biotechnologies? Adaptive Biotechnologies saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 9,100,000 shares, an increase of 7.6% from the March 15th total of 8,460,000 shares. Based on an average daily trading volume, of 1,490,000 shares, the short-interest ratio is presently 6.1 days. Currently, 6.6% of the shares of the stock are short sold. View Adaptive Biotechnologies' Short Interest. When is Adaptive Biotechnologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our ADPT earnings forecast. How can I listen to Adaptive Biotechnologies' earnings call? Adaptive Biotechnologies will be holding an earnings conference call on Tuesday, May 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Adaptive Biotechnologies' earnings last quarter? Adaptive Biotechnologies Co. (NASDAQ:ADPT) issued its quarterly earnings results on Wednesday, February, 14th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.02. The firm had revenue of $45.78 million for the quarter, compared to the consensus estimate of $50.15 million. Adaptive Biotechnologies had a negative net margin of 132.29% and a negative trailing twelve-month return on equity of 53.65%. What ETFs hold Adaptive Biotechnologies' stock? ETFs with the largest weight of Adaptive Biotechnologies (NASDAQ:ADPT) stock in their portfolio include ARK Genomic Revolution ETF (ARKG) and Amplify Treatments, Testing and Advancements ETF (GERM).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG). What guidance has Adaptive Biotechnologies issued on next quarter's earnings? Adaptive Biotechnologies issued an update on its first quarter 2024 earnings guidance on Tuesday, April, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $41.0 million-$43.0 million, compared to the consensus revenue estimate of $38.2 million. What is Chad Robins' approval rating as Adaptive Biotechnologies' CEO? 51 employees have rated Adaptive Biotechnologies Chief Executive Officer Chad Robins on Glassdoor.com. Chad Robins has an approval rating of 92% among the company's employees. This puts Chad Robins in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Adaptive Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptive Biotechnologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), QUALCOMM (QCOM), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Home Depot (HD), Inovio Pharmaceuticals (INO), PayPal (PYPL) and Tesla (TSLA). When did Adaptive Biotechnologies IPO? Adaptive Biotechnologies (ADPT) raised $200 million in an initial public offering on Thursday, June 27th 2019. The company issued 12,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers. Who are Adaptive Biotechnologies' major shareholders? Adaptive Biotechnologies' stock is owned by a number of institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (4.26%) and First Trust Direct Indexing L.P. (0.01%). Insiders that own company stock include Chad M Cohen, Chad M Cohen, Chad M Robins, Chad M Robins, Egon Durban, Euclidean Capital Llc, Francis Lo, Harlan S Robins, Harlan S Robins, Julie Rubinstein, Jyoti Palaniappan, Kyle Piskel, Lance Baldo, Michelle Renee Griffin, Nitin Sood, R Mark Adams, Stacy L Taylor and Tycho Peterson. View institutional ownership trends. How do I buy shares of Adaptive Biotechnologies? Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ADPT) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaYour Money is Not SafeAmerican AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptive Biotechnologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
